Wednesday, February 12, 2025
spot_img

Ignitis Group to present full-year 2024 results on 26 February

AB “Ignitis grupė” (hereinafter – the Group) will release its full-year 2024 results on Wednesday, 26 February 2025. It will be followed by an earnings call for investors and analysts to be held on the same day at 1:00 pm Vilnius / 11:00 am London time.

To join the earnings call, please register at:
https://edge.media-server.com/mmc/go/IgnitisFY2024results/

It will be also possible to join the earnings call by phone. To access the dial-in details please register here. After completing the registration, you will receive dial-in details on screen and via email. You will be able to dial in using the provided numbers and the unique pin or by selecting ‘Call me’ option and providing your phone details for the system to connect you in automatically as the earnings call starts.

All questions of interest can be directed to the Group’s Investor Relations team in advance, after registration or live during the earnings call.

Presentation slides will be available for download prior the call at:
https://ignitisgrupe.lt/en/reports-presentations-and-fact-sheets

The Integrated Annual Report 2024, fact sheet (in Excel) and other documents published together with the full-year results will be available for download at:
https://ignitisgrupe.lt/en/reports-presentations-and-fact-sheets

For additional information, please contact:

Communications
Valdas Lopeta
+370 621 77993
[email protected]

Investor Relations
Ainė Riffel-Grinkevičienė
+370 643 14925
[email protected]

Powered by SlickText.com

Hot this week

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Topics

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Eminent Closes Acquisition of Celts Project in Nevada

VANCOUVER, British Columbia, Feb. 12, 2025 (GLOBE...

Optiva Launches Agentic AI for Telecom BSS, Powered by Google’s Gemini Models

Award-winning BSS platform now seamlessly incorporates virtual generative AI...
spot_img

Related Articles

Popular Categories

spot_img